UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference
UNITY Biotechnology (NASDAQ: UBX) will present a corporate update at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UNITY Biotechnology (NASDAQ: UBX) will present a corporate update at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 11:10 a.m. ET. The event will be virtual, and a replay will be accessible for 90 days afterward. UNITY focuses on developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging, particularly in age-related ophthalmologic and neurologic conditions. Interested investors can access the presentation through the Cowen conference portal or their website.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was -4.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, March 7, 2022, at 11:10 a.m. ET.
The presentation will be available through the Cowen conference portal and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Media Contact
Canale Communications
Jason Spark
Jason.spark@canalecomm.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.